Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
44 participants
INTERVENTIONAL
2007-11-30
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Sodium Tungstate
Sodium Tungstate
Sodium Tungstate, 200 mg BID, oral route during 6 weeks
2
Placebo
Placebo, BID, oral route during 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sodium Tungstate
Sodium Tungstate, 200 mg BID, oral route during 6 weeks
Placebo
Placebo, BID, oral route during 6 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In case of male gender, 18 to 65 years old
* In case of female gender, diagnosis of menopause
* Body weight changes \< 3 kg in the last 3 months
* In case of arterial hypertension or dyslipemia, no changes in dose in the last 2 months
Exclusion Criteria
* Evidence of secondary causes of obesity
* Diabetes, type II
* Concomitant treatment with drugs affecting body weight
* Previous surgical intervention of obesity
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundacio Clinic Barcelona
OTHER
Hospital Clinic of Barcelona
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hospital Clinic Barcelona
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Josep Vidal, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Clinic of Barcelona
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospiral Clinic de Barcelona
Barcelona, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hanzu F, Gomis R, Coves MJ, Viaplana J, Palomo M, Andreu A, Szpunar J, Vidal J. Proof-of-concept trial on the efficacy of sodium tungstate in human obesity. Diabetes Obes Metab. 2010 Nov;12(11):1013-8. doi: 10.1111/j.1463-1326.2010.01293.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT: 2006-000567-28
Identifier Type: -
Identifier Source: secondary_id
TROTA-1
Identifier Type: -
Identifier Source: org_study_id